|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2300072016 |
|
最近更新日期: Date of Last Refreshed on: |
2023-05-31 15:54:01 |
|
注册时间: Date of Registration: |
2023-05-31 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
人工智能辅助胃镜检查系统用于门诊胃镜检查患者的前瞻性、多中心、随机对照研究 |
|
Public title: |
Effect of an Artificial Intelligence Computer-Aided Detection and Diagnostic System on gastric neoplasm: A Multicenter Randomized Controlled Trial |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
人工智能辅助胃镜检查系统用于门诊胃镜检查患者的前瞻性、多中心、随机对照研究 |
|
Scientific title: |
Effect of an Artificial Intelligence Computer-Aided Detection and Diagnostic System on gastric neoplasm: A Multicenter Randomized Controlled Trial |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
诸炎 |
研究负责人: |
李全林 |
|
Applicant: |
Yan Zhu |
Study leader: |
Quanlin Li |
|
申请注册联系人电话: Applicant telephone: |
+86 159 0171 3084 |
研究负责人电话: Study leader's telephone: |
+86 135 6467 1882 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
zhuyan1992521@163.com |
研究负责人电子邮件: Study leader's E-mail: |
li.quanlin@zs-hospital.sh.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
上海市徐汇区枫林路180号 |
研究负责人通讯地址: |
上海市徐汇区枫林路180号 |
|
Applicant address: |
180 Fenglin Road, Shanghai, China |
Study leader's address: |
180 Fenglin Road, Shanghai, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
复旦大学附属中山医院 |
||
|
Applicant's institution: |
Zhongshan Hospital, Fudan University |
||
|
研究负责人所在单位: |
复旦大学附属中山医院 |
||
|
Affiliation of the Leader: |
Zhongshan Hospital, Fudan University |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
B2023-141R |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
复旦大学附属中山医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Zhongshan Hospital, Fudan University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2023-05-15 00:00:00 |
||
|
伦理委员会联系人: |
杨梦婕 |
||
|
Contact Name of the ethic committee: |
Meng-Jie Yang |
||
|
伦理委员会联系地址: |
上海市徐汇区枫林路180号 |
||
|
Contact Address of the ethic committee: |
180 Fenglin Road, Shanghai, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 21 3158 7871 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
ec@zs-hospital.sh.cn |
|
研究实施负责(组长)单位: |
复旦大学附属中山医院 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Primary sponsor: |
Zhongshan Hospital, Fudan University |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
上海市徐汇区枫林路180号 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Primary sponsor's address: |
180 Fenglin Road, Shanghai, China |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
经费或物资来源: |
无 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Source(s) of funding: |
N/A |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Target disease: |
gastric neoplasm |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究所处阶段: |
诊断试验新技术临床试验 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Study phase: |
Diagnostic New Technique Clincal Study |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究设计: |
随机交叉对照 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Study design: |
Cross-over |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究目的: |
通过多中心随机对照试验,验证人工智能辅助胃镜检查系统是否可以降低门诊胃镜检查患者的胃肿瘤漏诊率。 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Objectives of Study: |
To verify whether the AI-assisted gastricoscopy system can reduce the gastric neoplasia miss rate in outpatient gastroscopy by a multi-center randomized control trial. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
纳入标准: |
① 18岁以上,性别不限; ② 需要或有意愿进行门诊胃镜检查的受试者; ③ 能够自愿签署或者提供知情同意书; |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Inclusion criteria |
1.18 years old and above,male or female; 2.Has the indication of or is willing to undergooutpatient gastroscopy examination; 3. Willing to and has the ability to sign or provide an informed consent |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
排除标准: |
① 有胃手术史; ② 有明确的胃癌,累及胃的家族性息肉病或炎症性肠病病史; ③ 正行抗凝治疗,停药风险高或有凝血功能障碍,无法进行活检; ④ 严重慢性肾功能衰竭(肌酐清除率<30毫升/分钟); ⑤ 严重充血性心力衰竭(纽约心脏病协会III级或IV级); ⑥ 怀孕或哺乳期; ⑦ 高血压控制不佳(动脉收缩压>180毫米汞柱和/或动脉舒张压>100毫米汞柱); ⑧ 中度或大量活动性胃肠道出血(>100毫升/天); ⑨ 无法耐受镇静内镜检查; |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Exclusion criteria: |
1.History of gastric surgery; 2. Known gastric cancer, familial polyposis or inflammatory bowel disease involving the stomach; 3.Current anticoagulation therapy with a high risk of suspension, with high hemorrhagic risk to perform a polyp biopsy ; 4. Severe chronic renal failure (creatinine clearance<30 ml/min); 5. Severe congestive heart failure (New York Heart Association class III or IV); 6. Pregnancy or in lactation; 7.Poorly controlled hypertension (arterial systolic blood pressure >180 mm Hg and/or arterial diastolic blood pressure >100 mm Hg); 8.Moderate or massive active GI bleeding (>100 mL/day); 9.Unable to tolerate sedation endoscopy |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-05-01 00:00:00至 To 2024-03-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2023-06-01 00:00:00 至 To 2024-01-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
每个中心的其中一名研究人员使用 1:1 随机数生成器对患者进行 1:1 随机化分组。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Patients were 1:1 randomized by using a 1:1 random number generator by one of the investigators in each institution. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
患者对分组盲。病理医师不了解研究设计和目的,并且对分组盲。数据收集人员和分析人员对分组盲。进行胃镜检查的医生了解分组情况。 |
|
Blinding: |
The patients are blinded to the grouping. The pathologists are not informed of the study design and aim and blinded to the grouping. The data collector and the analyst are blinded to the grouping. The endoscopists performing the gastroscopy examination know the grouping. |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
不共享原始数据 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Do not share raw data |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病历记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
case report form |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |